Loading company…
San Mateo oncology company developing small-molecule drugs for the Hippo-YAP pathway, led by VT3989.
Vivace Therapeutics, Inc. develops small-molecule therapeutics for the Hippo-YAP pathway, with its lead candidate VT3989, a YAP-TEAD inhibitor in a Phase 1 trial for advanced solid tumors. Founded in 2014 and headquartered in San Mateo, US, the company is led by CEO Sofie Qiao and has completed four deals. In February 2025 it raised USD 17.50 mn in Series D funding led by RA Capital Management, with participation from Canaan Partners and Cenova Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in